Vera Therapeutics, Inc. is a clinical-stage biotechnology company that develops targeted protein therapeutics to modulate immune system pathways. The company's foundational asset is atacicept, a self-administered subcutaneous fusion protein that inhibits B-cell activating factors to treat immunoglobulin A nephropathy (IgAN) and lupus nephritis. In addition to atacicept, Vera's pipeline includes MAU868, a monoclonal antibody for the treatment of BK viremia infections, and VT-109, a dual-inhibitor molecule for B cell-mediated autoimmune diseases. Originally founded as a gene-editing company called Trucode Gene Repair, the firm pivoted and rebranded as Vera Therapeutics in 2020 to focus on precision immunology.
